A citation-based method for searching scientific literature

M M Saiyed, P S Ong, L Chew. J Clin Pharm Ther 2017
Times Cited: 42







List of co-cited articles
64 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
Rena M Conti, Arielle C Bernstein, Victoria M Villaflor, Richard L Schilsky, Meredith B Rosenthal, Peter B Bach. J Clin Oncol 2013
80
26

Off-label prescribing among office-based physicians.
David C Radley, Stan N Finkelstein, Randall S Stafford. Arch Intern Med 2006
417
16

Association of Off-label Drug Use and Adverse Drug Events in an Adult Population.
Tewodros Eguale, David L Buckeridge, Aman Verma, Nancy E Winslade, Andrea Benedetti, James A Hanley, Robyn Tamblyn. JAMA Intern Med 2016
101
14


Off-label prescribing to children in the United States outpatient setting.
Alicia T F Bazzano, Rita Mangione-Smith, Matthias Schonlau, Marika J Suttorp, Robert H Brook. Acad Pediatr 2009
79
11

Ten common questions (and their answers) about off-label drug use.
Christopher M Wittich, Christopher M Burkle, William L Lanier. Mayo Clin Proc 2012
114
11

Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.
M Joerger, C Schaer-Thuer, D Koeberle, K Matter-Walstra, J Gibbons-Marsico, S Diem, B Thuerlimann, T Cerny. Eur J Clin Pharmacol 2014
17
29


Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
160
9


Prevalence of off-label use of oral oncolytics at a community cancer center.
Joseph A Kalis, Simon J Pence, Robert S Mancini, Dan S Zuckerman, Joseph R Ineck. J Oncol Pract 2015
12
33


Ethical and legal framework and regulation for off-label use: European perspective.
Christian Lenk, Gunnar Duttge. Ther Clin Risk Manag 2014
36
8

Off-label use of drugs in children.
Daniel A Frattarelli, Jeffrey L Galinkin, Thomas P Green, Timothy D Johnson, Kathleen A Neville, Ian M Paul, John N Van Den Anker. Pediatrics 2014
173
7

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Apostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, Jennifer J Wheler, Gerald S Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Rajyalakshmi Luthra,[...]. Clin Cancer Res 2012
347
7

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
7

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Tracy L Stockley, Amit M Oza, Hal K Berman, Natasha B Leighl, Jennifer J Knox, Frances A Shepherd, Eric X Chen, Monika K Krzyzanowska, Neesha Dhani, Anthony M Joshua,[...]. Genome Med 2016
124
7

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
Funda Meric-Bernstam, Lauren Brusco, Kenna Shaw, Chacha Horombe, Scott Kopetz, Michael A Davies, Mark Routbort, Sarina A Piha-Paul, Filip Janku, Naoto Ueno,[...]. J Clin Oncol 2015
263
7

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, Céline Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Trédan, Marie-Ange Massiani, Cécile Mauborgne,[...]. Lancet Oncol 2015
556
7


Unlicensed and off-label uses of medicines: definitions and clarification of terminology.
Jeffrey K Aronson, Robin E Ferner. Br J Clin Pharmacol 2017
22
13

Off-label use of targeted therapies in oncology.
Dominique Levêque. World J Clin Oncol 2016
10
30

Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.
Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo, Mamoru Kato, Yutaka Fujiwara, Akihiko Shimomura, Takafumi Koyama, Hiroki Kakishima, Mayuko Kitami, Hiromichi Matsushita,[...]. Cancer Sci 2019
64
7

The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting.
Marta Herrero Fernandez, Raquel Molina Villaverde, Monica Arroyo Yustos, Fatima Navarro Expósito, Jose Luis Lopez Gonzalez, Maria Rosario Luque Infantes, Melchor Alvarez-Mon Soto. Front Pharmacol 2019
3
100

Increasing off-label use of antipsychotic medications in the United States, 1995-2008.
G C Alexander, S A Gallagher, A Mascola, R M Moloney, R S Stafford. Pharmacoepidemiol Drug Saf 2011
281
4


A Multicenter Evaluation of Off-Label Medication Use and Associated Adverse Drug Reactions in Adult Medical ICUs.
Pamela L Smithburger, Mitchell S Buckley, Mark A Culver, Sarah Sokol, Ishaq Lat, Steven M Handler, Levent Kirisci, Sandra L Kane-Gill. Crit Care Med 2015
19
10


Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
4

Practical, legal, and ethical issues in expanded access to investigational drugs.
Jonathan J Darrow, Ameet Sarpatwari, Jerry Avorn, Aaron S Kesselheim. N Engl J Med 2015
76
4

Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.
Jonathan P Jarow, Steven Lemery, Kevin Bugin, Sean Khozin, Richard Moscicki. Ther Innov Regul Sci 2016
38
5

Risks and benefits of phase 1 oncology trials, 1991 through 2002.
Elizabeth Horstmann, Mary S McCabe, Louise Grochow, Seiichiro Yamamoto, Larry Rubinstein, Troy Budd, Dale Shoemaker, Ezekiel J Emanuel, Christine Grady. N Engl J Med 2005
310
4

A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients.
S K Takemoto, B W Pinsky, M A Schnitzler, K L Lentine, L M Willoughby, T E Burroughs, S Bunnapradist. Am J Transplant 2007
122
4

Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review.
Janet A Butler, Paul Roderick, Mark Mullee, Juan C Mason, Robert C Peveler. Transplantation 2004
353
4

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Christophe Massard, Stefan Michiels, Charles Ferté, Marie-Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loic Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari,[...]. Cancer Discov 2017
269
4

OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty, Jianjiong Gao, Sarah M Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E Rudolph, Rona Yaeger, Tara Soumerai, Moriah H Nissan,[...]. JCO Precis Oncol 2017
653
4

The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey.
M Kelsey Kirkwood, Amy Hanley, Suanna S Bruinooge, Elizabeth Garrett-Mayer, Laura A Levit, Caroline Schenkel, Jerome E Seid, Blase N Polite, Richard L Schilsky. J Oncol Pract 2018
56
4

[Off-label use of oncology drugs: national survey results].
Eva González-Haba Peña, María José Agustín Ferrández, Irene Mangues Bafalluy, Nicolás Alfredo López, María Dolores Fraga Fuentes, Roberto Marín Gil, María José Martínez Bautista, Ana Clopés Estela. Farm Hosp 2015
2
100


Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
4

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
945
4

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Milan Radovich, Patrick J Kiel, Stacy M Nance, Erin E Niland, Megan E Parsley, Meagan E Ferguson, Guanglong Jiang, Natraj R Ammakkanavar, Lawrence H Einhorn, Liang Cheng,[...]. Oncotarget 2016
48
4

Prospective Clinical Study of Precision Oncology in Solid Tumors.
Davendra P S Sohal, Brian I Rini, Alok A Khorana, Robert Dreicer, Jame Abraham, Gary W Procop, Yogen Saunthararajah, Nathan A Pennell, James P Stevenson, Robert Pelley,[...]. J Natl Cancer Inst 2015
64
4

Off-label medication use in adult critical care patients.
Ishaq Lat, Scott Micek, Jeffrey Janzen, Henry Cohen, Keith Olsen, Curtis Haas. J Crit Care 2011
33
6


Reasons for and frequency of off-label drug use.
Svetlana Goločorbin Kon, Ivana Iliković, Momir Mikov. Med Pregl 2015
13
15

Off-label use of medicines: consensus recommendations for evaluating appropriateness.
Madlen Gazarian, Maria Kelly, John R McPhee, Linda V Graudins, Robyn L Ward, Terence J Campbell. Med J Aust 2006
115
4


Two decades of off-label prescribing in children: a literature review.
Shamala Balan, Mohamed Azmi Ahmad Hassali, Vivienne S L Mak. World J Pediatr 2018
17
11



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.